Mathematics and Statistics Awareness Month Lecture Series
April is Mathematics and Statistics Awareness Month. As part of our celebration we sponsor a special lecture series. Our goal is to increase public understanding of and appreciation for mathematics and statistics.
The next lecture in this series will be at 4:00 on Wednesday, 25 April 2018.
Life After a Mathematics Degree
Dr. Bobby J. Prochaska
4:00 Wednesday, 25 April 2018
Mouton Hall Room 117
Bob Prochaska, a native of Alexandria, Louisiana, received his BS in mathematics from the University of Southwestern Louisiana in 1963. He continued his formal education at Colorado State University, where he received a MS in mathematics and statistics; followed by a PhD in mathematics from Clemson University.
After seven years in academics, Bob ventured into the "real world." During the next 35 years he held various positions in line and staff management in consumer products, textiles, apparel, and related industries. Most recently, Bob served as President and Chief Operating Officer at Scovill Fasteners. He held similarly responsible management positions in other publically held and private corporations, such as Gerber Childrenswear (Pres), Kayser-Roth Corporation (EVP) and Milliken & Company (GM).
In addition to corporate management responsibilities; utilizing his practical business experience and academic background, Bob has served as consultant in operations and general management, business information systems and process improvement. We are pleased to add that Bob has travelled full circle from SLI to USL to UL Lafayette, and is currently teaching our operations research course.
Previous Lectures in the Series
An Introduction to Early Stage Clinical Trial Design
Dr. Daniel Zelterman
4:00 Thursday, 6 April 2017
Oliver Hall Auditorium (112)
Refreshments at 3:30 in the lobby.
Abstract: We are familiar with the large randomized clinical trials reported in the news. But these Phase III trials are the culmination of many smaller studies which are also of interest. In Phase I trials, we seek an estimated safe dose of the drug to be administered to patients with a low probability of toxic side-effects. From a statistical point of view, how should such experiments be conducted? In Phase II trials we want to show a treatment effect when compared to a historical control group. In Phase II we also want to avoid treating patients with an inferior treatment so we may include an early stopping rule. We will talk about the challenges available to statisticians in designing these experiments.
Daniel Zelterman, PhD, is Professor of Epidemiology and Public Health in the Division of Biostatistics at Yale University. Before moving to Yale in 1995, he was on the faculty of the University of Minnesota and the University at Albany. He is an elected Fellow of the American Statistical Association and serves as an Associate Editor of Biometrics and several other statistical journals.
Dr. Zelterman works in areas of applied statistics motivated by intriguing questions posed in a variety of scientific areas. He works closely with researchers in other disciplines, chiefly cancer and HIV. His work involves the design of clinical trials, experiments, and surveys, with particular emphasis on the identification of clear and relevant endpoints in such applications. He is also involved in the analysis and interpretation of the results of these investigations. He is the author of six books on statistics and statistical methods, incorporating SAS and R software.
In his spare time, Dr. Zelterman plays the bassoon in several amateur chamber and orchestral groups in the New Haven area. He has backpacked hundreds of miles of the Appalachian Trail.
Frogs and Cancer and Patents! Oh My! Setting Your Career on a Yellow Brick Road with Math
Dr. Seth Boudreaux
13 April 2016